What is the global market size of Genome Editing Market?

The Global Genome Editing Market was valued at USD 5.25 Billion in 2021, and it is expected to reach a value of USD 17.02 Billion by 2028, at a CAGR of 18.30% over the forecast period (2022 - 2028). Read More

Global Genome Editing Market Size, Share, Growth Analysis, By Technology(CRISPR, TALEN), By Delivery Method(Ex-vivo, In-vivo), By Mode(Contract, In-house), By End Use(Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes) - Industry Forecast 2024-2031

Report ID: SQSG35J2001 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 117 | Figures: 77

Global Genome Editing Market News

In May 2022, CRISPR-Combo is a method developed by scientists at the University of Maryland College of Agriculture and Natural Resources to edit multiple genes in plants while simultaneously changing the expression of other genes. This new tool will allow genetic engineering combinations to work together to improve crop functionality and breeding.
In May 2022, GenScript Introduces GMP Single-Strand and Double-Strand DNA Services to Aid in the Development of Gene and Cell Therapy.
In January 2022,The researchers and developers working on the plant in England will have easier access to genetic technology such as Gene editing.
In February 2022, Integrated DNA Technologies unveiled Alt-R & HDR Donor Blocks, an improved solution for increasing homology-directed repair (HDR) rates. Alt-R HDR Donor Blocks are the latest addition to IDT’s complete portfolio of Alt-R CRISPR genome editing solutions.
In February 2022, Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. announced the positive interim data from an ongoing Phase I clinical study of their lead in vivo genome editing candidate, NTLA-2001 (Investigational Crispr Therapy For Transthyretin (Attr) Amyloidosis).
In April 2021, Researchers at Harvard's Wyss Institute for Biologically Inspired Engineering created Retron Library Recombineering (RLR), a new gene-editing tool that allowed for the simultaneous execution of millions of genetic experiments, resulting in higher editing rates.
In March 2021, A team of Nanyang Technological University researchers created a diagnostic test called VaNGuard (Variant Nucleotide Guard) that is based on CRISPR technology. This test can detect mutated SARS-CoV-2 strains, which will increase the use of CRISPR genome editing technology in diagnostics.
In November 2020, Eli Lilly and Company collaborated with Precision BioSciences, Inc. to develop potential in-vivo therapeutics for genetic disorders using the latter company's proprietary ARCUS genome editing platform. Such collaborations have heightened market competition, resulting in organic revenue growth.

Global Genome Editing Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Genome Editing Market size was valued at USD 4.81 billion in 2019 and is poised to grow from USD 5.88 billion in 2023 to USD 36.06 billion by 2031, growing at a CAGR of 22.3% in the forecast period (2024-2031).

The market's various competitors are challenged to provide innovative offerings that enable communication in addressing changing technologies, business practices, and security needs. Partnerships, strategic mergers, and acquisitions are expected to be the most effective ways for industry players to gain quick access to emerging markets while also improving technological capabilities. Custom vectors for cell line editing and engineering are provided by well-established companies such as Merck KGaA and Thermo Fisher Scientific. Such services are anticipated to grow in the coming years, fueling revenue growth. Contract manufacturers would benefit from the rapidly increasing demand from gene therapy Genome Editing Market players. 'Thermo Fisher Scientific Inc.', 'CRISPR Therapeutics AG', 'Editas Medicine, Inc.', 'Intellia Therapeutics, Inc.', 'Sangamo Therapeutics, Inc.', 'Precision Biosciences, Inc.', 'Cellectis S.A.', 'Merck KGaA', 'Lonza Group AG', 'Horizon Discovery Group plc', 'Genscript Biotech Corporation', 'Agilent Technologies, Inc.', 'New England Biolabs, Inc.', 'Takara Bio, Inc.', 'Synthego Corporation', 'OriGene Technologies, Inc.', 'Genewiz, Inc.', 'Eurofins Scientific SE', 'Bio-Rad Laboratories, Inc.', 'Qiagen N.V.'

Governments in various countries around the world have made significant investments in the field of genomics in recent years, which has played a significant role in the development of new technologies in genome editing. Furthermore, the availability of government funding has enabled academic and government institutes to conduct in-depth genome editing/engineering research. For instance, in March 2020, the Ministry of Innovation, Science, and Industry (Science) announced a USD 15 million grant to Genome Canada to support 11 genomic research projects in the health, agriculture, and environment sectors. Provincial governments, businesses, and research partners will also contribute to these projects, with a total investment of USD 29.7 million. Ovarian and cervical cancer research is among the projects. The number of genomics research projects has increased significantly as a result of significant government investments in genomics. As a result, the genome editing market is expected to grow during the forecast period.

The COVID-19 pandemic has prompted major pharmaceutical and biotechnology firms, as well as players in the genomic market, to invest in vaccine research and development. The increased demand for vaccines and antiviral candidates has pushed genome editing/engineering technologies to the forefront, these factors are expected to drive the Genome Editing Market in the upcoming years.

North America dominated the genome editing market in 2021, accounting for 38.4% of total revenue. The dominance of the Genome Editing Market in the region is due to the availability of strong research, as well as a commercial base for advanced therapeutic development, as well as a large number of clinical studies being undertaken for gene and stem cell therapies in the region. On the other hand, the market in the Asia Pacific is expected to expand at a rapid rate over the projected period. China unveiled its 10 most significant agricultural breakthroughs in November 2020, one of which was gene-editing technology, demonstrating strong Genome Editing Market penetration.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Global Genome Editing Market Size, Share, Growth Analysis, By Technology(CRISPR, TALEN), By Delivery Method(Ex-vivo, In-vivo), By Mode(Contract, In-house), By End Use(Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes) - Industry Forecast 2024-2031

Global Genome Editing Market News

Global Genome Editing Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Genome Editing Market?

Who are the key vendors in the Global Genome Editing Market?

What is the key driver of Global Genome Editing Market?

What is the key market trend for Global Genome Editing Market?

Which region accounted for the largest share in Global Genome Editing Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300